The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback